Company Overview of Calithera Biosciences, Inc.
Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company was founded in 2010 and is headquartered in South San Francisco, California.
343 Oyster Point Boulevard
South San Francisco, CA 94080
Founded in 2010
Key Executives for Calithera Biosciences, Inc.
Calithera Biosciences, Inc. Key Developments
Similar Private Companies By Industry
|Cornerstone BioPharma Holdings, Inc.||United States|
|Zeneca Holdings Inc.||United States|
|Astra Usa, Inc||United States|
|Xel Pharmaceuticals, Inc.||United States|
|JDP Therapeutics, Inc.||United States|
Recent Private Companies Transactions
July 1, 2014
October 7, 2013
To contact Calithera Biosciences, Inc., please visit www.calithera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.